16/04/08

Research deficiencies ‘delaying HIV prevention’

Flaws in research design have prevented progress in identifying HIV-prevention interventions Copyright: European Communities

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Research deficiencies ‘delaying HIV prevention’</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p><span>Deficiencies in research design have held back progress in identifying HIV prevention interventions, say Stephen W. Lagakos and Alicia R. Gable in the <em>New England Journal of Medicine</em>.</span></p>
<p><span>Shortcomings have included inadequate pre-trial research and sample size, poor site preparation and lack of community engagement.</span></p>
<p><span>The authors say the research community should increase investment in the development of safe, easy-to-use biomedical interventions because, in the 15–20 years it may take to achieve an efficacious vaccine, 20–60 million new HIV infections could occur.</span></p>
<p><span>Preclinical and early-stage clinical testing, and prioritisation of products for later-stage testing should be improved to maximise use of research resources, and reduce further testing of unsafe or ineffective products. </span></p>
<p><span>Better methods for assessing and improving adherence to intervention trials and risk-taking behaviour should also be prioritised.</span></p>
<p><span>Because young women are disproportionately affected by the epidemic in many regions, Lagakos and Gable urge sponsors and researchers to take steps to evaluate the safety and efficacy of preventive products in pregnant women.</span></p>
<p><span>They also say sponsors should reconsider the usual financial and time constraints placed on investigators conducting HIV-prevention trials.</span></p>
<p><span><a target="_blank" href="http://content.nejm.org/cgi/content/full/358/15/1543" rel="noopener noreferrer"><span>Link to full article in the <em>New England Journal of Medicine</em></span></a></span></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/opinions/research-deficiencies-delaying-hiv-prevention/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/opinions/research-deficiencies-delaying-hiv-prevention/",null,true])
</script>
</div>

Deficiencies in research design have held back progress in identifying HIV prevention interventions, say Stephen W. Lagakos and Alicia R. Gable in the New England Journal of Medicine.

Shortcomings have included inadequate pre-trial research and sample size, poor site preparation and lack of community engagement.

The authors say the research community should increase investment in the development of safe, easy-to-use biomedical interventions because, in the 15–20 years it may take to achieve an efficacious vaccine, 20–60 million new HIV infections could occur.

Preclinical and early-stage clinical testing, and prioritisation of products for later-stage testing should be improved to maximise use of research resources, and reduce further testing of unsafe or ineffective products.

Better methods for assessing and improving adherence to intervention trials and risk-taking behaviour should also be prioritised.

Because young women are disproportionately affected by the epidemic in many regions, Lagakos and Gable urge sponsors and researchers to take steps to evaluate the safety and efficacy of preventive products in pregnant women.

They also say sponsors should reconsider the usual financial and time constraints placed on investigators conducting HIV-prevention trials.

Link to full article in the New England Journal of Medicine